Table 3. Ingenuity pathway analyses of the impact of genes that are differentially expressed in Brodmann Area 9 from subjects with schizophrenia at the level of the syndrome (Schizophrenias) and those within the MRDS.
| Top canonical pathways | P |
Top disease and biofunction |
|||||
|---|---|---|---|---|---|---|---|
| Diseases and disorders | P | Molecular and cellular functions | P | Physiological system development and function | P | ||
| Schizophrenias | |||||||
| Hepatic fibrosis/hepatic stellate cell activation | 1.32E−05 | Neurological disease | 2.99E−03 to 8.85E−09 | Amino acid metabolism | 2.99E−03 to 1.06E−09 | Tissue development | 2.99E−03 to 7.55E−07 |
| Triacylglycerol biosynthesis | 4.11E−03 | Organismal injury and abnormalities | 2.99E−03 to 2.51E−07 | Molecular transport | 2.99E−03 to 1.06E−09 | Organismal development | 2.99E−03 to 1.29E−06 |
| Hepatic cholestasis | 1.15E−02 | Skeletal and muscular disorders | 2.99E−03 to 6.30E−06 | Small-molecule biochemistry | 2.99E−03 to 1.06E−09 | Organ development | 2.99E−03 to 1.42E−06 |
| Regulation of the epithelial–mesenchymal transition pathway | 1.57E−02 | Inflammatory disease | 2.63E−03 to 8.77E−06 | Cellular development | 2.99E−03 to 7.55E−07 | Reproductive system development and function | 2.99E−03 to 1.42E−06 |
| FGF signalling | 2.62E−02 | Inflammatory response | 2.99E−03 to 8.77E−06 | Cell morphology | 2.99E−03 to 1.01E−06 | Nervous system development and function | 2.99E−03 to 1.84E−06 |
| MRDS | |||||||
| Hepatic fibrosis/hepatic stellate cell activation | 2.58E−03 | Neurological disease | 6.54E−03 to 1.29E−08 | Cellular movement | 5.07E−03 to 1.05E−06 | Tissue morphology | 6.54E−03 to 3.32E−07 |
| LXR/RXR activation | 6.83E−03 | Organismal injury and abnormalities | 6.54E−03 to 3.32E−07 | Molecular transport | 6.54E−03 to 2.00E−06 | Cardiovascular system development and function | 6.54E−03 to 1.06E−05 |
| IL-12 signalling and production in macrophages | 8.17E−03 | Cardiovascular disease | 6.54E−03 to 1.06E−05 | Amino acid metabolism | 5.86E−03 to 2.61E−06 | Organismal development | 4.91E−03 to 1.06E−05 |
| Thiosulfate disproportionation III (rhodanese) | 9.80E−03 | Inflammatory disease | 6.54E−03 to 1.06E−05 | Small-molecule biochemistry | 6.54E−03 to 2.61E−06 | Tissue development | 6.54E−03 to 1.76E−05 |
| Hepatic cholestasis | 1.48E−02 | Inflammatory response | 6.54E−03 to 1.06E−05 | Cell-to-cell signalling and interaction | 6.54E−03 to 1.06E−05 | Organ development | 6.53E−03 to 5.02E−05 |
| Non-MRDS | |||||||
| Cardiomyocyte differentiation via BMP receptors | 7.77E−04 | Neurological disease | 8.71E−03 to 8.01E−07 | Molecular transport | 6.54E−03 to 4.46E−06 | Organ development | 8.71E−03 to 6.56E−06 |
| Role of NANOG in mammalian embryonic stem cell pluripotency | 1.55E−03 | Cancer | 8.71E−03 to 1.41E−05 | Cellular growth and proliferation | 8.71E−03 to 1.19E−05 | Reproductive system development and function | 8.71E−03 to 6.56E−06 |
| Hepatic fibrosis/hepatic stellate cell activation | 6.52E−03 | Gastrointestinal disease | 8.71E−03 to 1.41E−05 | Amino acid metabolism | 1.46E−03 to 1.35E−05 | Nervous system development and function | 8.71E−03 to 3.75E−05 |
| L-carnitine biosynthesis | 6.54E−03 | Organismal injury and abnormalities | 8.71E−03 to 1.41E−05 | Small-molecule biochemistry | 6.54E−03 to 1.35E−05 | Tissue development | 8.71E−03 to 2.08E−04 |
| Thiosulfate disproportionation III (rhodanese) | 6.54E−03 | Renal and urological disease | 8.71E−03 to 5.53E−05 | Cellular function and maintenance | 8.71E−03 to 1.39E−05 | Skeletal and muscular system development and function | 8.71E−03 to 2.82E−04 |
Abbreviations: BMP, bone morphogenetic protein; FGF, fibroblast growth factor; IL-12, interleukin 12; LXR/RXR, liver X receptor/ retinoid X receptor; MRDS, muscarinic receptor-deficit schizophrenia.